Back to Search Start Over

Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.

Authors :
Minervini, Andrea
Minervini, Andrea
Mir, Maria
Cerrato, Clara
Rebez, Giacomo
Autorino, Riccardo
Hampton, Lance
Campi, Riccardo
Kriegmair, Maximilian
Linares, Estefania
Hevia, Vital
Musquera, Maria
DAnna, Mauricio
Roussel, Eduard
Albersen, Maarten
Pavan, Nicola
Claps, Francesco
Antonelli, Alessandro
Marchioni, Michele
Paksoy, Nail
Erdem, Selcuk
Derweesh, Ithaar
Meagher, Margaret
Minervini, Andrea
Minervini, Andrea
Mir, Maria
Cerrato, Clara
Rebez, Giacomo
Autorino, Riccardo
Hampton, Lance
Campi, Riccardo
Kriegmair, Maximilian
Linares, Estefania
Hevia, Vital
Musquera, Maria
DAnna, Mauricio
Roussel, Eduard
Albersen, Maarten
Pavan, Nicola
Claps, Francesco
Antonelli, Alessandro
Marchioni, Michele
Paksoy, Nail
Erdem, Selcuk
Derweesh, Ithaar
Meagher, Margaret
Publication Year :
2024

Abstract

BACKGROUND AND OBJECTIVE: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the basis of clinical trial data from the tyrosine kinase inhibitor (TKI) era. Comparative analyses of CN for patients treated with immuno-oncology (IO) versus TKI agents are sparse. Our objective was to compare CN timing and outcomes among patients who received TKI versus IO therapy. METHODS: This was a multicenter retrospective analysis of patients who underwent CN using data from the REMARCC (Registry of Metastatic RCC) database. The cohort was divided into TKI versus IO first-line therapy groups. The primary outcome was all-cause mortality (ACM). Secondary outcomes included cancer-specific mortality (CSM). Multivariable analysis was used to identify factors predictive for ACM and CSM. The Kaplan-Meier method was used to analyze 5-yr overall survival (OS) and cancer-specific survival (CSS) with stratification by primary systemic therapy and timing in relation to CN. KEY FINDINGS AND LIMITATIONS: We analyzed data for 189 patients (148 TKI + CN, 41 IO +CN; median follow-up 23.2 mo). Multivariable analysis revealed that a greater number of metastases (hazard ratio [HR] 1.06; p = 0.015), greater primary tumor size (HR 1.10; p = 0.043), TKI receipt (HR 2.36; p = 0.015), and initiation of systemic therapy after CN (HR 1.49; p = 0.039) were associated with worse ACM. A greater number of metastases at diagnosis (HR 1.07; p = 0.011), greater primary tumor size (HR 1.12; p = 0.018), TKI receipt (HR 5.43; p = 0.004), and initiation of systemic therapy after CN (HR 2.04; p < 0.001) were associated with worse CSM. Kaplan-Meier analyses revealed greater 5-yr rates for OS (51% vs 27%; p < 0.001) and CSS (83% vs 30%; p < 0.001) for IO +CN versus TKI + CN. This difference persisted in a subgroup analysis

Details

Database :
OAIster
Notes :
application/pdf
Publication Type :
Electronic Resource
Accession number :
edsoai.on1432080926
Document Type :
Electronic Resource